N Anthony Coles Cerevel Therapeutics Holdings, Inc. (CERE) insider trading activity

N Anthony Coles is of Cerevel Therapeutics Holdings, Inc.. Currently has a direct ownership of 0 shares of CERE, which is worth approximately $0. The most recent transaction as insider was on Nov 03, 2023, when has been sold 61,401 shares (Common Stock) at a price of $3.5 per share, resulting in proceeds of $214,903. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

100.0% 12M change

Total Value Held $0

N ANTHONY COLES Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 03 2023	BUY Exercise of conversion of derivative security	$214,903 $3.5 p/Share	61,401 Added 48.92%	64,105 Common Stock
Nov 02 2023	SELL Open market or private sale	$972,308 $25.19 p/Share	38,599 Reduced 93.45%	2,704 Common Stock
Nov 02 2023	BUY Exercise of conversion of derivative security	$135,096 $3.5 p/Share	38,599 Added 48.31%	41,303 Common Stock
Sep 07 2023	SELL Open market or private sale	$1,203,500 $24.07 p/Share	50,000 Reduced 94.87%	2,704 Common Stock
Sep 07 2023	BUY Exercise of conversion of derivative security	$175,000 $3.5 p/Share	50,000 Added 48.68%	52,704 Common Stock
Jul 11 2023	SELL Open market or private sale	$1,501,500 $30.03 p/Share	50,000 Reduced 94.87%	2,704 Common Stock
Jul 11 2023	BUY Exercise of conversion of derivative security	$175,000 $3.5 p/Share	50,000 Added 48.68%	52,704 Common Stock
Jun 01 2023	SELL Open market or private sale	$1,630,000 $32.6 p/Share	50,000 Reduced 94.87%	2,704 Common Stock
Jun 01 2023	BUY Exercise of conversion of derivative security	$175,000 $3.5 p/Share	50,000 Added 48.68%	52,704 Common Stock
May 04 2023	SELL Open market or private sale	$1,601,000 $32.02 p/Share	50,000 Reduced 94.87%	2,704 Common Stock
May 04 2023	BUY Exercise of conversion of derivative security	$175,000 $3.5 p/Share	50,000 Added 48.68%	52,704 Common Stock
Apr 11 2023	SELL Open market or private sale	$1,253,000 $25.06 p/Share	50,000 Reduced 94.87%	2,704 Common Stock
Apr 11 2023	BUY Exercise of conversion of derivative security	$175,000 $3.5 p/Share	50,000 Added 48.68%	52,704 Common Stock
Mar 03 2023	SELL Open market or private sale	$81,570 $27.19 p/Share	3,000 Reduced 52.59%	2,704 Common Stock
Mar 03 2023	BUY Exercise of conversion of derivative security	$10,500 $3.5 p/Share	3,000 Added 34.47%	5,704 Common Stock
Mar 02 2023	SELL Open market or private sale	$1,274,170 $27.11 p/Share	47,000 Reduced 94.56%	2,704 Common Stock
Mar 02 2023	BUY Exercise of conversion of derivative security	$164,500 $3.5 p/Share	47,000 Added 48.6%	49,704 Common Stock
Feb 07 2023	SELL Open market or private sale	$1,665,500 $33.31 p/Share	50,000 Reduced 94.87%	2,704 Common Stock
Feb 07 2023	BUY Exercise of conversion of derivative security	$175,000 $3.5 p/Share	50,000 Added 48.68%	52,704 Common Stock
Jan 05 2023	SELL Open market or private sale	$1,516,500 $30.33 p/Share	50,000 Reduced 94.87%	2,704 Common Stock
Jan 05 2023	BUY Exercise of conversion of derivative security	$175,000 $3.5 p/Share	50,000 Added 48.68%	52,704 Common Stock
Dec 09 2022	SELL Open market or private sale	$1,343,000 $26.86 p/Share	50,000 Reduced 94.87%	2,704 Common Stock
Dec 09 2022	BUY Exercise of conversion of derivative security	$175,000 $3.5 p/Share	50,000 Added 48.68%	52,704 Common Stock

Also insider at

CRSP

CRISPR Therapeutics AG Healthcare

Director

REGN

REGENERON PHARMACEUTICALS, INC. Healthcare

Director

YMTX

YUMANITY THERAPEUTICS, INC. Healthcare

Executive Chair

NAC

N Anthony Coles

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CERE shares.

Notify only if

Value

Insider Trading

Get notified when an Cerevel Therapeutics Holdings, Inc. insider buys or sells CERE shares.

Notify only if

Operation

Value

Type

News

Receive news related to Cerevel Therapeutics Holdings, Inc.

Track Activities on CERE

Account